Anatomical Therapeutic Chemical • L04AJ02 • ravulizumab

L Antineoplastic and immunomodulating agents

L01 Antineoplastic agents

L02 Endocrine therapy

L03 Immunostimulants

L04 Immunosuppressants

L04A Immunosuppressants

L04AA Selective immunosuppressants

L04AB Tumor necrosis factor alpha (tnf-alpha) inhibitors

L04AC Interleukin inhibitors

L04AD Calcineurin inhibitors

L04AE Sphingosine-1-phosphate (S1P) receptor modulators

L04AF Janus-associated kinase (JAK) inhibitors

L04AG Monoclonal antibodies

L04AH Mammalian target of rapamycin (mTOR) kinase inhibitors

L04AJ Complement inhibitors

L04AJ01 eculizumab Indicated for: complement-mediated disorders

L04AJ02 ravulizumab Indicated for: complement-mediated disorders

L04AJ03 pegcetacoplan Indicated for: complement-mediated disorders

L04AJ05 avacopan Indicated for: ANCA-associated vasculitis

L04AJ06 zilucoplan Indicated for: myasthenia gravis

L04AJ07 crovalimab Indicated for: paroxysmal nocturnal haemoglobinuria

L04AJ08 iptacopan Indicated for: complement-mediated disorders

L04AJ09 danicopan Indicated for: complement-mediated disorders

L04AK Dihydroorotate dehydrogenase (DHODH) inhibitors

L04AL Neonatal fragment crystallizable receptor (fcrn) inhibitors

L04AX Other immunosuppressants